A fatal viral infection, AIDS (Acquired Immune Deficiency Syndrome), is brought on by HIV (Human Immune-Deficient Virus) infection. Nearly all AIDS patients pass away by the mid-1990s. AIDS used to be the number one killer in the US (1993). A Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) or ritonavir pharmacologically enhanced Protease Inhibitor (PI/r) is added to the double nucleoside (NRTI) backbone of HAART. In comparison to 2NRTIs/NNRTI or 2NRTIs/PI/r combinations, triple NRTI combinations are less effective. First-line antiretroviral therapy is quickly shifting to more practical and safe regimens. There are currently three double NRTI co-formulations on the market, and medications including 3TC, FTC, and tenofovir have minimal rates of mitochondrial toxicity.Antiviral medication combinations and Highly Active Antiretroviral Therapy (HAART) have been developed after a decade of arduous research and development for practically all HIV infection therapies. 80%–90% of HIV/AIDS patients still respond to HAART for life-saving and lethal AIDS episode control thanks to the development of HAART. However, this particular HIV treatment is incurable. Patients with HIV/AIDS must regularly and maybe permanently take HAART drugs.
